The Pulse Podcast

The Pulse Podcast

Brought to you by the Harvard Biotech Club
Country USA
Language EN
Episodes 18
Latest 22.10.2026

The Pulse Podcast explores stories from the biotechnology world and features conversations with key figures in the field. Presented by the Harvard Biotech Club, it aims to inspire the next generation of biotech leaders. Each episode offers a deep dive into developments, careers, and ideas shaping biotech. More information is available at hbcpulse.substack.com.

Episodes

  • Todd Golub: Pioneering Cancer Genomics and Collaborative Science
    Todd Golub: Pioneering Cancer Genomics and Collaborative Science 22.10.2026 1h 8m
    Dr Todd Golub is Director of the Broad Institute of MIT and Harvard, and a founding core member of the institute. He is also a member of the faculty of the Dana-Farber Cancer Institute and Harvard Medical School. Todd pioneered the application of genomics to cancer biology and therapeutic discovery. He is one of the first researchers to use genomic approaches to molecularly characterize human tumors, laying the foundation for the use of genomics to classify, diagnose, and treat cancer. Throughout his career, Todd is deeply committed to patient-focused research. He has advocated for and helped...
  • Carl Novina: From Academic Discovery to Company Creation
    Carl Novina: From Academic Discovery to Company Creation 02.10.2026 1h 24m
    Dr. Carl Novina is a physician-scientist, biotech founder, and Science Partner at Flagship Pioneering. Before joining Flagship, he spent nearly two decades as a principal investigator at Harvard Medical School, Dana-Farber Cancer Institute, and Broad Institute, where he studied RNA biology, cancer immunology, and therapeutic innovation. He received his MD from Columbia, his PhD from Tufts, and completed postdoctoral training in the laboratory of Nobel Laureate Phillip Sharp at MIT.Carl has co-founded multiple biotech companies, including Microbial Machines, Dynamic Cell Therapies, and NextRNA...
  • Tasuku Kitada: Building a Biotech Strand by Strand
    Tasuku Kitada: Building a Biotech Strand by Strand 15.09.2026 50m
    Dr. Tasuku Kitada is the co-founder, President, Head of R&D, and a board director at Strand Therapeutics, a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancer, autoimmune disease, and in vivo cell engineering.Tasuku received his B.S. in Biophysics and Biochemistry from the University of Tokyo, earned his Ph.D. in Molecular Biology from UCLA, and completed postdoctoral training at MIT, where his work helped pioneer synthetic gene circuits built from mRNA. He later earned an MBA from the Wharton School at the University of Pennsylvania and worked as a senio...
  • Ryan Flynn: The Wonderful World of GlycoRNA
    Ryan Flynn: The Wonderful World of GlycoRNA 01.09.2026 1h 1m
    Ryan Flynn is pioneering a brand new field of biology. His seminal report of glycosylated RNA (glycoRNA) in 2021 reimagined the way we think about the cell surface and intercell communication. The discovery of glycoRNA revealed that cells intentionally express RNA on their surfaces and these RNAs interact powerfully with the immune system with potential implications in autoimmune disease and cancer immunology. Some of Ryan’s early work in these areas was adopted by Orna Therapeutics which was ultimately acquired by Eli Lilly for $2.4 billion.Ryan is no stranger to the wonderful world of RNA. H...
  • Chuan He: Philosophies on the Wall Between Academia and Industry
    Chuan He: Philosophies on the Wall Between Academia and Industry 27.05.2026 41m
    Chuan He is a world-renowned epigeneticist, a Wolf Prize laureate, and a recent inductee of the National Academy of Sciences. Chuan’s lab at the University of Chicago has spun out numerous companies including Ellis Bio (DNA methylation detection technologies) and Aferna Bio (plant biology). His discovery of the first RNA demethylase introduced a new layer of transcriptional regulation, and his subsequent work resulted in epigenetic based tools for detecting biomarkers of cancer, created super-crops that are more productive and resistant to drought, identified novel therapeutic targets, and ena...
  • Mark Namchuk: The Art of the Argument Between Science and Business at Every Level
    Mark Namchuk: The Art of the Argument Between Science and Business at Every Level 27.03.2026 59m
    Mark Namchuk is the Executive Director of Therapeutics Translation at Harvard Medical School. Before he joined Harvard, Mark had a 24-year research and development career in the biotech industry, working in a number of areas, including drug discovery, translational science and pharmaceutical development. Mark began his industry career at Cubist Pharmaceuticals as head of the enzymology group. Then Mark spent 17 years at Vertex, holding a number of senior research positions, including senior vice president of North American research and interim global head of research. In 2015, Mark joined Alke...
  • Vicki Sato: Building Modern Biotech Through the Pull and Push
    Vicki Sato: Building Modern Biotech Through the Pull and Push 20.03.2026 1h 19m
    Dr Vicki Sato is a pioneering biotech leader who helped shape the modern biotech industry. She currently serves on the board or in the advisory role for several biotech companies, including Vir Biotechnology, Denali Therapeutics, Allogene Therapeutics, and as a venture partner at ARCH Venture Partners. Vicki started her career as an academic scientist. She was a professor in the Department of Cell and Developmental Biology at Harvard. She later made a bold leap into biotech industry, initially joining Biogen and ultimately becoming Chief Scientific Officer and then President of Vertex Pharmace...
  • James Collins: Doing Good Science with an Underdog Spirit
    James Collins: Doing Good Science with an Underdog Spirit 08.03.2026 1h 11m
    James Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT. Jim serves as a director at the MIT Jameel Clinic, a member of the Harvard-MIT Health Sciences & Technology Faculty, a core founding faculty member of the Wyss Institute, and a member of the Broad Institute. Jim is also an elected member of all three national academies. As one of the founders of synthetic biology, Jim has pioneered research by using synthetic biology and AI to develop next-generation diagnostics and therapeutics, particularly for infectious diseases such as E...
  • Tim Harris: a Journey through 50 years of Biotechnology
    Tim Harris: a Journey through 50 years of Biotechnology 02.03.2026 1h 14m
    Tim Harris is a molecular biologist, biochemist and geneticist. He is also a science and business leader with over 40 years of experience in a range of molecular research areas. Tim is currently an Operating Partner at SV Health Investors. Outside of SV, he holds a seat on the Board of Directors of Phenome TX in Edinburgh and is a visiting professor at Columbia University.Before joining SV, Tim served in several senior management positions including Executive VP of Corporate Development at Repertoire Immune Medicines, Executive VP of R&D at Bioverativ (now part of Sanofi-Genzyme), the Senior V...
  • Stephanie Oestreich: Leadership across biotech and orchestras
    Stephanie Oestreich: Leadership across biotech and orchestras 22.02.2026 43m
    Stephanie Oestreich is Managing Director of the Myeloma Investment Fund (MIF), a venture philanthropy fund focused on therapies and technologies for multiple myeloma. She is the chair of the McCloy Alumni Association. She is also a faculty member at MIT, and an advisor at multiple drug development companies and healthcare investment companies.Previously she worked as International Business Leader at Roche and Novartis. Then she also worked as CBO at Galecto, VP at Mnemo Therapeutics, a Venture Partner at RA Capital, and EVP at Evotec where she built its North American investment arm and starte...
  • Luke Timmerman: Daring to Traverse Biotech and Mountains
    Luke Timmerman: Daring to Traverse Biotech and Mountains 15.02.2026 1h 7m
    Luke Timmerman is a biotech journalist, author, entrepreneur, and philanthropist. As an award-winning journalist, Luke has been covering biotech since 2001. He is the founder and editor of Timmerman Report, a leading biotech industry newsletter. He hosts “The Long Run”, a biotech-focused podcast that has featured more than 200 biotech leaders. Luke was named one of the 100 most influential people in biotech in 2015 by Scientific American. He earned a bachelor’s degree in journalism from the University of Wisconsin and was awarded a Knight Science Journalism Fellowship at MIT. Luke also founded...
  • Bill Sellers: A Nonlinear Journey in Advancing Cancer Therapeutics Across Academia and Industry
    Bill Sellers: A Nonlinear Journey in Advancing Cancer Therapeutics Across Academia and Industry 09.02.2026 53m
    Dr. Bill Sellers is a physician scientist and a leading cancer researcher who has held major roles across academia and industry, including Core member of the Broad Institute and Professor at Dana-Farber Cancer Institute and Harvard Medical School. Bill helped pioneer cancer genomics, including the discovery of EGFR mutations in lung cancer and the creation of the Cancer Cell Line Encyclopedia (CCLE). Bill was a former VP and Global Head of Oncology at Novartis. In this episode, * Bill Sellers shares his path from his upbringing in Massachusetts through Georgetown, UMassMed, UCSF, and into onco...
  • Melissa McCracken: A Scientist’s Journey into Biotech VC
    Melissa McCracken: A Scientist’s Journey into Biotech VC 01.02.2026 47m
    Melissa McCracken is a partner at Nextech Invest, a leading oncology-focused venture capital firm. She is a board member for multiple private and public biotech companies. Melissa is a scientist by training from UCLA with her research on engineered immunity for cancer. She also completed her postdoctoral fellowship at Stanford University where she expanded her research in the field of immuno-oncology. Prior to Nextech, Melissa was a senior associate at Third Rock Ventures and helped build and launch Celsius Therapeutics, which is now part of AbbVie. In this episode,* Melissa traces her career...
  • Soufiane Aboulhouda: A story of startups and serendipity
    Soufiane Aboulhouda: A story of startups and serendipity 14.01.2026 58m
    Soufiane (Souf) is a synthetic biologist by training from Harvard Medical School. During his PhD, he founded Nucleate, a non-profit biotech organization that represents the largest global community of bio-innovators and offers numerous free entrepreneurship programs for academic trainees.In this episode,* Souf shares his background and how he got into research during his undergraduate years before starting his PhD at Harvard where he joined George Church’s lab. * He describes why he got involved with the Harvard Biotech Club and the various initiatives he led as co-president, including Activat...
  • John Maraganore: The Importance of Being Unreasonable
    John Maraganore: The Importance of Being Unreasonable 21.12.2025 54m
    Dr. John Maraganore, founding CEO of Alnylam Pharmaceuticals and co-founder of City Therapeutics, discusses his journey from a Greek immigrant household to pioneering RNA interference (RNAi) therapeutics. He highlights Alnylam’s growth from a startup to a major biotech company, leading to the first FDA-approved RNAi therapy. John shares insights on decision-making, mentorship, and the future of RNA therapies. He also discusses his new ventures, including Corsera Health, focusing on cardiovascular disease prevention using RNAi. * John shares his upbringing in Chicago, growing up with Greek immi...
  • George Church: Embracing Outliers in Science and in Life
    George Church: Embracing Outliers in Science and in Life 24.07.2025 1h 1m
    Dr. George Church, is a genetics professor at Harvard Medical School and the Wyss Institute. George is a pioneer in synthetic biology and personalized genomics. In 2017, Time magazine named him as one of the 100 most influential people in the world. In addition to being a scientist, George is also a prolific serial entrepreneur. He has co-founded over 50 biotech startups through his lab at Harvard. George also serves as a Faculty Advisor for the Harvard Biotech Club.In this episode,* George shares his career path to become a professor at Harvard Medical School and the Wyss Institute, where his...
  • Chris Bahl: From Protein Geek to Biotech CEO
    Chris Bahl: From Protein Geek to Biotech CEO 12.06.2025 43m
    Chris Bahl is the Co-founder and CEO of AI Proteins. He also established the Boston Protein Design and Modeling Club (BPDMC), where he serves as Co-organizer. After completing his PhD in biochemistry from Dartmouth, Chris joined David Baker Lab at the University of Washington, where he pioneered the ability to design mini-proteins as a postdoc with the future Nobel Laureate. Chris later joined Institute of Protein Innovation as one of the founding faculty members, with co-appointments at Boston Children’s Hospital and Harvard Medical School. In 2021, Chris left academia and co-founded AI Prote...
  • Peter Kolchinsky: Create Your Own Luck by Doing Things Outside of Class
    Peter Kolchinsky: Create Your Own Luck by Doing Things Outside of Class 08.05.2025 1h 49m
    Peter Kolchinsky: Scientist, investor, author, founder of No Patient Left Behind, and co-founder of RA Capital Management.Peter is a virologist by training from Harvard University. After finishing his PhD, he went on to create RA Capital, a leading biotech venture capital firm. In this episode, Peter shares his journey to starting RA Capital and becoming a venture capital investor.* He shares his background, growing up in an entrepreneurial family.* He shares the origin of why he started the Harvard Biotech Club during his PhD.* We discuss how Peter started RA Capital and his career as a ventu...
  • Madalyn Won: Making the Jump from Academia into Consulting
    Madalyn Won: Making the Jump from Academia into Consulting 02.03.2025 32m
    Maddie is a parasitologist by training from Harvard University. After her PhD graduation, she joined McKinsey as an associate. In this episode, Maddie shared her journey from the lab to consulting. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit hbcpulse.substack.com
  • Emily Gaudiano: From Lab Bench to Biotech Venture Capital
    Emily Gaudiano: From Lab Bench to Biotech Venture Capital 17.01.2025 40m
    * Emily Gaudiano reflects on her PhD in Arlene Sharpe Lab at Harvard Medical School and shares the pivotal moments that influenced her career.* With experience in recruiting interns for VC, she offers valuable insights and actionable strategies for graduates aspiring to break into biotech VC.* She shares her experience as an intern and later as a full-time Associate in MPM BioImpact and SV Health Investors, offering a glimpse into life in the Biotech VC industry.Emily is an energetic person. She likes traveling, scuba-diving, and cooking.Guest speaker: Emily GaudianoPodcast hosts: Fang Xie & Y...

Popular in

The podcast also appears in the podcast charts of these countries.